Clinical Trial Update: A Study to Evaluate Allogenic Bone-Marrow Mesenchymal Stromal Cell Product StromaForte in Aging Frailty Patients [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating the allogeneic bone-marrow mesenchymal stromal cell product StromaForte in aging frailty patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aging Frailty

Drugs mentioned

• StromaForte (human allogeneic bone-marrow-derived mesenchymal stromal cells)

Snippet

Sponsor: Cellcolabs Clinical SPV Limited | Conditions: Aging Frailty | Phase 1, Phase 2 | Status: COMPLETED